Clinical trials: Acute Phase
Acute Pain
A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty
The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating acute pain after an abdominoplasty.
- Trial name
- NCT05034952
- Testing
- VX-548, HB/APAP
- Where
- 7 sites in United States
- Volunteers
- 303 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia
This phase II trial studies the best dose and how well liposomal cytarabine-daunorubicin CPX-351 (CPX-351) works in treating patients with newly diagnosed acute myeloid leukemia and who are at risk for not responding well to…
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
- Trial name
- NCT02286726
- Testing
- Laboratory Biomarker Analysis, Liposome-encapsulated Daunorubicin-Cytarabine
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- M.D. Anderson Cancer Center
Non-ST Elevation Acute Coronary Syndrome
Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.
The purpose of this study is to determine if ticagrelor is as effective as clopidogrel in rate of onset and degree of platelet inhibition for patients with non-ST elevation of acute coronary syndrome (NSTE-ACS) undergoing ad hoc…
- Trial name
- NSTE-ACS (NCT02052635)
- Testing
- ticagrelor, clopidogrel
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Aggressive Systemic Mastocytosis, Mast Cell Leukemia
Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
This phase 2 trial studies ibrutinib to see how well it works in treating patients with systemic (affecting the entire body) mastocytosis that has spread to other parts of the body and usually cannot be cured or controlled with…
- Conditions
- Aggressive Systemic Mastocytosis, Mast Cell Leukemia, Systemic Mastocytosis
- Trial name
- NCT02415608
- Testing
- Ibrutinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jason Robert Gotlib
Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia
Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia
This randomized phase II trial studies how well cytarabine with or without SCH 900776 works in treating adult patients with relapsed acute myeloid leukemia.
- Conditions
- Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- Trial name
- NCT01870596
- Testing
- Cytarabine, CHK1 Inhibitor SCH 900776, Laboratory Biomarker Analysis
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Myelodysplastic Syndrome, Acute Myelogenous Leukemia
Phase II 5-Azacytidine Plus VPA Plus ATRA
5-aza is a chemotherapy drug with activity in leukemia and myelodysplastic syndromes (MDS). Researchers hope that valproic acid (VPA) and all-trans retinoic acid (ATRA)will increase the effects of 5-aza.
- Trial name
- NCT00326170
- Testing
- 5-Azacytidine (5-aza), Valproic Acid, All-Trans Retinoic Acid (ATRA)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
This research study tests an investigational drug called DS-3201b. An investigational drug is a medication that is still being studied and has not yet been approved by the United States Food and Drug Administration (FDA).
- Trial name
- NCT03110354
- Testing
- DS-3201b
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Daiichi Sankyo
Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
This phase II trial studies the side effects and best dose of bortezomib when given together with daunorubicin and cytarabine and to see how well it works in treating older patients with previously untreated acute myeloid…
- Conditions
- Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00742625
- Testing
- daunorubicin hydrochloride, cytarabine, bortezomib
- Where
- 22 sites in United States
- Volunteers
- 95 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
AML is the most common acute leukemia in adults. Most patients can undergo allogeneic stem cell transplantation as a possible cure; however, many patients are not candidates for allogeneic transplant due to age, overall health…
- Trial name
- NCT02771197
- Testing
- Fludarabine, Melphalan, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Northside Hospital, Inc.
Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
The safety and efficacy of midostaurin (PKC412), a novel investigational drug, will be evaluated on the basis of response rate, when administered to patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL)
- Conditions
- Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell, Hematological Non-mast Cell Lineage Disease (AHNMD)
- Trial name
- NCT00233454
- Testing
- Midostaurin
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Jason Robert Gotlib
Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Rollover Study of BMS-354825 in Patients With CML and Ph+ALL
To assess the safety of dasatinib (BMS-354825) in subjects with Imatinib resistant or intolerant chronic myelogenous leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) who are resistant…
- Trial name
- NCT01030718
- Testing
- dasatinib
- Volunteers
- 54 people
- Sponsor
- Bristol-Myers Squibb
Glucocorticosteroid Refractory Acute GVHD
Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)
The purpose of this study is to determine if Tocilizumab is a safe and effective treatment for steroid-refractory acute graft versus host disease.
- Trial name
- NCT01757197
- Testing
- Toclizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Weill Medical College of Cornell University
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with dexamethasone in participants with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma…
- Trial name
- NCT02518113
- Testing
- LY3039478, Dexamethasone
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Acute Non-cardioembolic Ischemic Stroke
Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.
The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of antiplatelet therapy in patients following a recent non…
- Trial name
- PACIFIC-STROKE (NCT04304508)
- Testing
- BAY2433334
- Where
- 197 sites in United States, Australia and 21 more
- Volunteers
- 1,808 people
- Sponsor
- Bayer
Myelogenous Leukemia, Acute, Leukemia, Lymphocytic, Acute
Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)
This study of SCH 900776 (MK-8776) will evaluate its safety and tolerability when given in combination with cytarabine to participants with acute leukemias.
- Conditions
- Myelogenous Leukemia, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Myelogenous Leukemia, Chronic, Aggressive Phase
- Trial name
- NCT00907517
- Testing
- MK-8776, Cytarabine
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
This clinical trial is studying how well giving fludarabine phosphate and melphalan together with total-body irradiation followed by donor stem cell transplant works in treating patients with hematologic cancer or bone marrow…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00856388
- Testing
- fludarabine phosphate, melphalan, total-body irradiation
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Roswell Park Cancer Institute
Acute Myeloid Leukemia, Myelodysplastic Syndromes
PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)
CPKC412A2104 core had a 2 stage design. In stage 1, eight participants were treated. If at least one participant showed a clinical response, four more participants were recruited to stage 2.
- Trial name
- NCT00045942
- Testing
- Itraconazole, PKC412
- Where
- 4 sites in United States
- Volunteers
- 144 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
The study investigates if CPX-351 will be a) more effective than the standard intensive salvage AML treatment and b) more tolerable than the standard intensive salvage treatment regimens.
- Trial name
- NCT00822094
- Testing
- CPX-351, Intensive Salvage Therapy
- Where
- 42 sites in United States, Canada and 2 more
- Volunteers
- 126 people
- Sponsor
- Jazz Pharmaceuticals
Acute Myeloid Leukemia
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
This phase I/II trial studies the side effects and best dosing frequency of gemtuzumab ozogamicin when given in combination with granulocyte colony stimulating factor (G-CSF), cladribine, cytarabine and mitoxantrone (GCLAM) and…
- Trial name
- NCT03531918
- Testing
- Cladribine, Cytarabine, Gemtuzumab Ozogamicin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Lymphoma
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
RATIONALE: Giving chemotherapy with or without total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00547196
- Testing
- filgrastim, Busulfan, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.